west syndrome market

DelveInsight has launched a new report on “West Syndrome – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “West Syndrome – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the West Syndrome, historical and forecasted epidemiology as well as the West Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the West Syndrome Market Report:

1. The total diagnosed prevalent population of West Syndrome in the 7 major markets was 8,601 in 2020.
2. The diagnosed prevalent cases of West Syndrome patients in the United States were 4,265 in 2020.
3. Delvelnsight has also analyzed gender-specific data for West Syndrome, which clearly suggests that it is more prevalent among males than in females. It was found that in the United States the number of cases of West Syndrome in males and females was 2,559 and 1,706 respectively, in 2020.
4. The total diagnosed prevalent population of West Syndrome in the 7MM is expected to increase at a CAGR of 2.16% during the study period, i.e., 2018–2030.
5. In Japan, the diagnosed prevalence of West Syndrome was 1,166 in 2020.
6. In the EU5 countries, the diagnosed prevalence of West Syndrome was observed to be maximum in France with 784 cases, followed by the United Kingdom with 738 cases in 2020. While, the least number of cases were found in Spain, with 475 cases in 2020.

Key benefits of the report:

1. The West Syndrome market report covers a descriptive overview and comprehensive insight of the West Syndrome Epidemiology and West Syndrome  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The West Syndrome market report provides insights on the current and emerging therapies.
3. West Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The West Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the West Syndrome market.

Got queries? Click here to know more about the West Syndrome Market Landscape.

West Syndrome Overview

West syndrome is an age-related specific epileptic encephalopathy due to multiple and diverse causes. It is characterized by a unique type of seizure called epileptic (infantile) spasms and gross EEG abnormalities of hypsarrhythmia. Usually, West syndrome consists of a characteristic triad: infantile spasms, the arrest of psychomotor development, and hypsarrhythmia, although one element may be missing. West syndrome may be separated into two groups:  the symptomatic group, which is characterized by previous existence of brain damage signs (psychomotor retardation, neurologic signs, radiologic signs, or other types of seizures) or by a known etiology, and the smaller, cryptogenic group that is characterized by a lack of previous signs of brain damage and known etiology.

A specific cause for West Syndrome can be identified in approximately 70–75% of those affected. Any disorder that can lead to brain damage can be an underlying cause of West syndrome including trauma, brain malformations such as hemimegalencephaly or cortical dysplasia, infections, chromosomal abnormalities such as Down syndrome, neurocutaneous disorders such as tuberous sclerosis complex (TSC), Sturge Weber syndrome, incontinentia pigmenti (Bloch-Sulzberger syndrome), different metabolic/genetic diseases such as pyridoxine deficiency, nonketotic hyperglycemia, maple syrup urine disorder, phenylketonuria, mitochondrial encephalopathies, and biotinidase deficiency, Otahara’s syndrome, and an abnormality (mutation) in the ARX gene or CDKL5 gene located on the X chromosome.

West Syndrome Market 

The dynamics of the West Syndrome market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as GW Pharmaceuticals, BioPharm Solutions, and others during the forecasted period 2018-2030.

Learn more by requesting for sample @West Syndrome Market Landscape 

West Syndrome Pipeline Therapies and Key Companies 

1. Epidiolex (GWP42003-P): GW Pharmaceuticals
2. JBPOS0101: BioPharm Solutions 

West SyndromeMarket Drivers

1. Clinical Development Activities
2. Product Innovations and Technological Advancements
3. Support from Various Organizations
4. Growing Number of Births and Rising Prevalence of Infantile Spasms

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. West Syndrome Patient Share (%) Overview at a Glance

5. West Syndrome Market Overview at a Glance

6. West Syndrome Disease Background and Overview

7. West Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of West Syndrome 

9. West Syndrome Current Treatment and Medical Practices

10. Unmet Needs

11. West Syndrome Emerging Therapies

12. West Syndrome Market Outlook

13. Country-Wise West Syndrome Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. West Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

West Syndrome Pipeline 

West Syndrome Epidemiology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/